Global Tumor Tracking System Market Size By Type (Prostate Cancer, Gastric Cancer), By Application (Cancer Research Institutes, Radiotherapy Centers), By Region, And Segment Forecasts, 2023 to 2032

The Global Tumor Tracking System Market was valued at USD 1.1 billion in 2023 and is projected to reach USD 2.3 billion by 2031, expanding at a CAGR of 9.5% from 2023 to 2031. The market growth is fueled by the increasing prevalence of cancer globally, the rising demand for precision oncology, and technological advancements in real-time imaging and motion management systems. Tumor tracking systems enhance radiotherapy accuracy by accounting for tumor movement during treatment, thus improving therapeutic outcomes and reducing radiation damage to surrounding tissues. With the global shift towards personalized medicine and image-guided treatment protocols, demand for advanced tumor tracking technologies is set to rise substantially.

Drivers

1. Rising Cancer Incidence Globally:

An increase in cancer diagnoses, especially lung, liver, and breast cancers, is driving the adoption of tumor tracking systems to support effective radiotherapy treatment.

2. Technological Advancements in Radiotherapy:

The integration of AI, machine learning, and real-time imaging systems in oncology has revolutionized tumor tracking, allowing for greater accuracy and better treatment planning.

3. Growing Preference for Non-invasive Treatment:

As patients and healthcare providers lean towards less invasive cancer therapies, tumor tracking systems support these needs by enabling targeted radiotherapy without surgical intervention.

Restraints

1. High Equipment Costs:

The initial investment in tumor tracking systems, including associated imaging and radiotherapy machines, can be prohibitively expensive, limiting adoption in smaller clinics and developing regions.

2. Lack of Skilled Professionals:

Operating advanced tumor tracking systems requires a skilled workforce of oncologists, medical physicists, and radiologic technologists, which remains a challenge in many countries.

Opportunity

1. Expansion in Emerging Economies:

Countries in Asia-Pacific and Latin America are increasing their investments in cancer care infrastructure, providing growth opportunities for tumor tracking solution providers.

2. Integration with AI and Machine Learning:

Next-generation tumor tracking systems leveraging AI to analyze patient movement patterns and tumor behavior are opening new avenues for innovation and competitive differentiation.

Market by System Type Insights

The Real-time Image-Guided Tumor Tracking segment dominated the market in 2023 due to its capability to adjust radiation delivery in response to tumor movement, particularly during breathing. These systems significantly reduce the margin of error in radiation therapy, improving both efficacy and patient safety. Meanwhile, Respiratory Gated Tracking Systems are gaining popularity in lung and thoracic cancer treatment, expected to be the fastest-growing segment during the forecast period.

Market by End-use Insights

In 2023, Hospitals & Cancer Treatment Centers accounted for the largest revenue share, driven by their comprehensive infrastructure and funding capabilities for advanced treatment technologies. However, Specialty Oncology Clinics are projected to witness rapid growth, supported by increasing outpatient treatment trends and the decentralization of advanced care services.

Market by Regional Insights

North America held the largest share of the tumor tracking system market in 2023, supported by robust healthcare infrastructure, early adoption of advanced technologies, and the presence of key market players. Asia-Pacific is forecasted to register the highest CAGR through 2031, propelled by rising cancer rates, growing medical tourism, and rapid technological integration in countries like China, India, and South Korea.

Competitive Scenario

Key players in the market include Varian Medical Systems (Siemens Healthineers), Elekta AB, Accuray Incorporated, Brainlab AG, ViewRay Inc., and C-RAD AB. These companies are heavily investing in R&D, AI-based upgrades, and strategic partnerships to enhance their product portfolios.

Key Developments:

In 2024, Varian (Siemens Healthineers) launched a next-gen tumor tracking module integrating AI and motion management software for adaptive radiotherapy.

Elekta AB in 2023 expanded its oncology platform with a new feature enabling real-time motion compensation for mobile tumors.

Accuray Incorporated announced a strategic alliance in 2025 to deliver tumor tracking systems to leading cancer centers in Latin America.

Scope of Work – Global Tumor Tracking System Market

Report Metric Details

Market Size (2023) USD 1.1 Billion